Batroxobin
- Level
- Commodity
- Parent
- 51131800
- Below
- 0
- Links · KBLI
- 8
Definition
UNSPSC 51131818This classification denotes a protease inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47RYF40GA9. European Medicines Agency schedules Batroxobin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00675MIG. The term BATROXOBIN is an International Non-Proprietary Name (see WHO INN reference publication, Volume 27, No. 10 1973, List 13.). World Health Organization schedules camostat in its Anatomical Therapeutic Chemical (ATC) Classification. BATROXOBIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Batroxobin under HS 35079090 and SITC 51691. SMILES:. As of Q4 2014, BATROXOBIN remains the US FDA Preferred Term for this commodity. . Batroxobin bears US NLM identifiers UMLS ID C0035158 and NCI Concept Code C79483.
Same parent
Under 51131800 · 31Activities that produce or sell this
KBLI · 8Inherited from family 51130000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.